$2,580,000 of SANOFI US SERVICES INC lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"340B: Biologic/Small molecule drug negotiation eligibility within HR 7174/S.832 EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research Funding within LHHS appropriations; Delinking; Drug Pricing - General; Drug Price Negotiations within Inflation Reduction Act; Drug Pricing- General Issues; FDA Drug Development; FDA Issues - General; Issues related to HR 1 One Big Beautiful Bill; HR 6423/S864 HELP Copays Act; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5376:Inflation Reduction Act; HRSA - Type 1 Diabetes Screening within LHHS appropriations; Influenza Vaccines; Insurance Design/Utilization Management; Intellectual Property; International Reference Pricing; Most Favored Nation; Orphan Drug Negotiation within HR 5539/S 3131 Orphan Cures Act; Out of Pocket Cap; Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization; Patient Experience/Patient Focused Drug Development within the FDA/AG Appropriations; Pharmacy Benefit Managers (PBM) Reform; Rare Pediatric Priority Review Voucher Program Reauthorization within HR 7834; Rebate Pass Through; Respiratory Syncytial Virus (RSV) Access; Routine Immunization Rates; S. 864 HELP Copays Act: S. 1339 (118th): PBM Reform Act; S. 1375: HELP Copays Act; S. 1542 (118th) DRUG Act; S. 2027: Prescription Information Modernization Act; S.4504 / HR 8698 (118th): SCREEN for Type 1 Diabetes Act; Supply Chain; Tax Credits; Transplant; Vaccine Injury Compensation Program; Vaccines-General Issues. 340B; Medicare Negotiation, and Most Favored Nation. Supply Chain Issues; and Importation issues. Supply Chain issues; TRIP Waivers; and Vaccine Injury Compensation Program. S. 43: Skinny Labels, Big Savings Act; S. 2276 ETHIC Act; and Intellectual Property. Insulin; Pharmacy Benefits Managers (PBMs); Taxes- General Issues; Type 1 Diabetes Screening; and Vaccines - General Issues"
You can find more data on corporate lobbying on Quiver Quantitative.
SNY Hedge Fund Activity
We have seen 333 institutional investors add shares of SNY stock to their portfolio, and 336 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DODGE & COX removed 12,439,148 shares (-18.0%) from their portfolio in Q4 2025, for an estimated $602,801,112
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,999,880 shares (-51.1%) from their portfolio in Q4 2025, for an estimated $145,374,184
- CAPITAL RESEARCH GLOBAL INVESTORS added 1,650,018 shares (+inf%) to their portfolio in Q4 2025, for an estimated $79,959,872
- MORGAN STANLEY added 1,540,271 shares (+20.4%) to their portfolio in Q4 2025, for an estimated $74,641,532
- NUVEEN, LLC removed 1,539,745 shares (-50.0%) from their portfolio in Q4 2025, for an estimated $74,616,042
- BANK OF AMERICA CORP /DE/ removed 1,328,467 shares (-13.5%) from their portfolio in Q4 2025, for an estimated $64,377,510
- MILLENNIUM MANAGEMENT LLC removed 1,296,873 shares (-90.4%) from their portfolio in Q4 2025, for an estimated $62,846,465
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SNY Analyst Ratings
Wall Street analysts have issued reports on $SNY in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 10/27/2025
To track analyst ratings and price targets for SNY, check out Quiver Quantitative's $SNY forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
